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S. Scho¨nberger,1 R. Meisel,1 O. Adams,2 Y. Pufal,1 H. J. Laws,1 J. Enczmann,3 D. Dilloo4Major advances in the monitoring and treatment of viral infections after hematopoietic stem cell transplan-
tation (HSCT) have been achieved over the last decade. The appropriate extent of viral monitoring and
antiviral therapy remains controversial, and reports in pediatric patients receiving allogeneic unmanipulated
hematopoietic stem cells (HSCs) are sparse. A total of 40 pediatric patients who underwent HSCTwith
either peripheral blood stem cells (PBSCs, n5 30) or bone marrow (BM; n5 10) were prospectively mon-
itored every week for viral DNAemia (VDNA) by simultaneous detection of cytomegalovirus (CMV),
Epstein-Barr virus (EBV), human herpesvirus 6 (HHV6), human adenovirus (ADV), and polyoma BK virus
(BKV) using real-time TaqMan polymerase chain reaction (PCR). All patients received prophylactic acyclovir
and preemptive ganciclovir (GCV) when 500 copies/mg DNA (EBV/HHV6) or.1 copy/mg DNA (CMV) were
detected on 2 consecutive measurements. VDNA occurred in 25 of 40 recipients (CMV, 11/40 patients
[28%]; EBV, 19/40 [48%]; HHV6, 2/40 [5%]; ADV/BKV, 1/40) and was found exclusively after neutrophil en-
graftment and in most cases up to day1100. Recurrent VDNA (P5.028) and (readily treatable) viral disease
(P 5 .003) were observed predominantly in patients suffering from nonmalignant diseases, a cohort charac-
terized by delayed lymphocyte engraftment. VDNA occurred more frequently in HLA-mismatched HSCT
and in the 24 of 40 patients receiving antithymocyte globulin (ATG). The incidence of EBV, but not that of
CMV, was increased in the ATG group. Yet, in these patients, viral loads of both EBV and CMV were higher,
but with prompt initiation of preemptive GCV, no posttransplantation lymphoproliferative disorder or other
life-threatening morbidities occurred. HHV6was typically detected at low viral loads (\102 copies/mg DNA),
with only 5% of HSC recipients fulfilling our HHV6 criteria for triggering GCV treatment. In multivariate anal-
ysis, ATG treatment, HLAmismatch, recipient CMV seropositivity, and stem cell source, but not severe acute
graft-versus-host disease were identified as independent risk factors for VDNA. This comprehensive viral
monitoring program with defined thresholds for initiation of preemptive GCV effectively prevents the
development of critical viral disease, even in high-risk patients receiving ATG.
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Viral infections constitute a significant cause of
morbidity andmortality after allogeneic hematopoietic
stem cell transplantation (HSCT). The predominant
infections are cytomegalovirus (CMV), Epstein-Barr
virus (EBV), and herpesvirus 6 (HHV6), affecting
primarily the lungs, gastrointestinal tract, central
nervous system, and hematopoietic system. Patients
with fulminate EBV replication are at risk for develop-
ing posttransplantation lymphoproliferative disorder
(PTLD) [1,2]. The prevalence of human adenovirus
(ADV) and polyoma BK virus (BKV) is increasing as
well, with a particularly aggressive course of viral
disease and a higher rate of mortality seen in T cell–
depleted transplant recipients [1].
Table 1. Patient Characteristics
Characteristic Number (n 5 40)
Age at transplantation, years, median (range) 6.5 (0.1-19.4)
Sex, n (%)
Male 22 (55%)
Female 18 (45%)
Underlying disease, n (%)
Acute lymphocytic leukemia 13 (33%)
Acute myelogenous/bilinear leukemia 9 (22%)
Juvenile myelomonozytic leukemia 4 (10%)
Chronic myelogenous leukemia 2 (5%)
Lymphoma 2 (5%)
Immunodeficiencies 5 (12.5%)
Other nonmalignant diseases 5 (12.5%)
Stem cell source, n (%)
BM 8 (20%)
PBSCs 32 (80%)
Type of donor, n (%)
Related 18 (45%)
Unrelated 22 (55%)
HLA match
10/10 23 (66%)
9/10 6 (17%)
7/10 and 8/10 6 (17%)
Conditioning regimen
TBI + etoposide/cyclophosphamide 12 (30%)
TBI + eoposide + cyclophosphamide 2 (5%)
Busulfan + cyclophosphamide 8 (20%)
Busulfan + cyclophosphamide
+ melphalan/etoposide
10 (25%)
No conditioning 3 (7%)
Other 5 (13%)
GVHD prophylaxis
No ATG 16 (40%)
Cyclosporine A 10 (25%)
Cyclosporine A + methotrexate 6 (15%)
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infections have been achieved because of the availability
of novel pharmaceutical agents and cell therapy strate-
gies. The establishment of polymerase chain reaction
(PCR)-based qualitative and quantitative monitoring
of viral DNAemia has allowed for optimal management
of antiviral treatment. The appropriate extent of viral
monitoring and the critical time window for initiating
PCR-guided preemptive antiviral therapy remain con-
troversial, however. Recent studies on the screening
and management of viral infections have focused on
CMV, and comprehensive data on viral DNAemia
and disease, including CMV and other relevant viruses
in the posttransplantation settings, such as EBV,
HHV6, ADV, and BKV, are sparse. In addition, most
previous studies have analyzed predominantly adult
transplantation cohorts. Reconstitution of immune
effector cells differs critically between children and
adults, and thus the incidence and course of viral infec-
tions posttransplantation may follow different courses,
warranting separate evaluation of pediatric HSCT
recipients. Here, we report our results on a prospective
and comprehensive PCR-guided viral monitoring
program for simultaneous detection of CMV, EBV,
HHV6, ADV, and BKV in a representative pediatric
cohort comprising 40 children and adolescents who
underwent allogeneic HSCT without ex vivo T cell
depletion for either inborn errors ormalignant diseases.ATG 24 (60%)
Cyclosporine A + ATG 4 (10%)
Cyclosporine A + methotrexate + ATG 12 (30%)
Cyclosporine A + methotrexate + ATG + MMF 4 (10%)
Other 4 (10%)
BM indicates bone marrow; PBSCs, peripheral blood stem cells; TBI,
total body irradiation; GVHD, graft-versus-host disease; ATG,
antithymocyte globulin.PATIENTS AND METHODS
Patient Cohort
A total of 40 consecutive pediatric patients under-
going HSCT at our center for malignant disease (MD
group; n5 30) or nonmalignant disease (NMD group;
n 5 10, including 5 patients with severe combined
immunodeficiency [SCID]) were included in this
prospective viral monitoring program for quality
assurance. Parents provided informed consent on the
transplantation procedure, including extended viral
monitoring. Conditioning therapy according to
patients’ age and disease was based on the guidelines
of the respective study protocols of the ‘‘Gesellschaft
fu¨r Pa¨diatrische Onkologie und Ha¨matologie’’
(GPOH) and the ‘‘Pa¨diatrische Arbeitsgemeinschaft
fu¨r Knochenmark- und Blutstammzelltransplanta-
tion’’ (PA¨D-AG-KBT). Patients received unmanipu-
lated peripheral blood stem cells (PBSCs) (n 5 30)
or bone marrow (BM) (n5 10), with ATG (ATG-Fre-
senius; Fresenius, Bad Homburg, Germany) at a dose
of 60 mg/kg body weight as part of the conditioning
regimen in 24 of the 40 patients. In 35 patients,
high-resolution molecular typing of HLA-A,
HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 was
performed [3], and the other 5 patients were matched
on the basis of low-resolution molecular typing ofHLA-A, HLA-B, and HLA-DRB1. Table 1 provides
details on patient, disease, and transplant characteris-
tics of our cohort.
Viral Monitoring Using the Real-Time TaqMan
Technique
Viral load of CMV, EBV, HHV6, BKV, and ADV
was prospectively monitored in peripheral blood every
week by real-time TaqMan-PCR until day 1 100
and/or cessation of immunosuppressive therapy and
in monthly intervals thereafter if chronic graft-
versus-host disease (GVHD) was observed. In case of
positive values, monitoring was repeated in the same
week to confirm the results and start preemptive
therapy as soon as possible. For viral monitoring,
DNA extraction was automatically performed from
whole blood (CMV, EBV, HHV6, ADV) and serum
(BKV) using an EZ1DNABlood Kit (Qiagen, Hilden,
Germany) and the EZ1 VirusMini Kit (Qiagen). Then
5 mL of the eluate was tested by in-house PCR for
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primers and the fluorogenic TaqMan probe were
selected using Primer Express software (PE Applied
Biosystems, Weiterstadt, Germany) using standard
concentrations as recommended by the manufacturer.
PCR runs were performed with an ABI 7500 sequence
detector system (Applied Biosystems, Darmstadt,
Germany). DNA standard plasmids encompassing
the amplified region were serially diluted to generate
standard graphs of the CT values. The CT values of
the unknown samples were plotted on the standard
curves, and the numbers of specific genomes were
calculated and corrected for the quantity of DNA
determined by the number of b-actin copies (1 ng
DNA 5 333 copies of b-actin). Thus, the final results
were expressed as copies of the viral genome per mg of
DNA. The sensitivities of the TaqMan PCRs were
\5 plasmid copies/assay.
Preemptive Antiviral Therapy
At the start of conditioning, all patients received
antiviral prophylaxis with acyclovir based on pretrans-
plantation HSV and CMV serology (HSV- and CMV-
IgG of both donor and recipient negative, 3 5 mg/kg
body weight/day; HSV- or CMV-IgG of either donor
or recipient positive, 3  10 mg/kg or 3  15 mg/kg
body weight, respectively). Intravenous immunoglobu-
lin (0.5 g/kg body weight/day) was administered on
day21, day 121, and thereafter if the patient’s immu-
noglobulin level dropped below the age-matched
normal level. PCR thresholds for initiation of antiviral
therapy were set at viral DNA levels exceeding 500
copies/mg DNA (EBV/HHV6) or 1 copy/mg DNA
(CMV, ADV, BKV) on 2 consecutive measurements.
Recurrent viral DNAemia was defined as intermittent
drop below the PCR thresholds for at least 3 weeks
(range, 3-24 weeks). In case of CMV-, EBV-, and
HHV6-DNAemia, preemptive treatment with ganci-
clovir (GCV) at an induction dose of 2 5mg/kg body-
weight/daywas started andcontinueduntil the viral load
dropped below the PCR thresholds. GCV-resistant
DNAemia of CMV, EBV, and HHV6 was treated
with foscarnet or cidofovir. Viral disease was defined
according to previously published guidelines [4].
Statistical Analysis
Statistical comparisons between the patients with
and without viral DNAemia were performed using
Fisher’s exact test for categorical parameters. For anal-
ysis of acute GcHD (aGVHD) and chronic GVHD
(cGVHD), only patients with evidence of donor
engraftment and survival beyond day 1100 (for
cGVHD) were considered evaluable, and both param-
eters were graded according to previously described
criteria [5,6]. Lymphocyte engraftment was evaluated
at 2, 3, 6, 9, and 12 months and defined asachievement of absolute lymphocyte counts above
the second standard deviation of age-dependent
reference values (0-2 years, .2500/mL; 2-5 years,
.1500/mL; .5 years, .1000/mL) [7]. Statistical anal-
yses, such as the Pearson c2 test, were performed using
SPSS version 17.0 (SPSS Inc, Chicago, IL), with
P values #.05 indicating statistical significance. To
estimate the cumulative probability of cause-specific
events in the presence of other competing events, 1
minus Kaplan-Meier estimates were used. Eighteen
possible risk factors for viral DNAemia were studied
by univariate analysis using Cox regression. Only those
patient, disease, and transplant variables with a P value
\.20 on univariate analysis were entered into the final
multivariate analysis to determine factors that inde-
pendently affected the probability of viral DNAemia.RESULTS
In this T cell-replete well–HLA-matched cohort
of pediatric HSCT recipients, viral DNA was moni-
tored on a weekly basis until the end of immunosup-
pressive therapy and at monthly intervals thereafter if
cGVHD was observed. Viral DNA was detected in
25 of 40 patients (63%) over a median follow-up
period of 3.7 years (range, 0.2-5.8 years). Most patients
tested positive for CMV (11/40 patients [28%]) or
EBV (19/40 [48%]), with other viruses seen only rarely
(HHV6, 2/40 patients [5%]; ADV/BKV, 1/40 [2.5%]).
Viral DNAemia was observed exclusively after
neutrophil engraftment and predominantly in the first
3 months (up to day 1100). The median time to first
detection of viral DNA was 77 days (range, 12-919
days) and median time of GCV treatment was 25
days (range, 12-147 days). During preemptive therapy,
no toxicities, such as renal or hematologic impairment,
were observed. The times to neutrophil and platelet
recovery were 18 days (range, 8-28 days) and 22 days
(range, 15-58 days), respectively, and lymphocyte
engraftment based on age-matched criteria [7] was
widely distributed in 30 of 40 patients (75%). Five
patients (12.5%) did not reconstitute during the entire
observation period of 12 months, and 5 patients
(12.5%) died before meeting the lymphocyte engraft-
ment criteria. Patients without lymphocyte engraft-
ment within the first 2 months after HSCT showed
a statistically nonsignificant trend toward a greater
risk for viral DNAemia (Figure 1). None of the 10
children who underwent transplantation for nonma-
lignant diseases displayed lymphocytic engraftment
at 2 months, whereas 11 of 30 patients (37%) with ma-
lignancies fulfilled this criterion. Accordingly, among
the 10 patients with a nonmalignant disease, 8 (80%)
exhibited viral DNAemia, and 6 of these 8 patients
tested positive at least twice. The risk for recurrent
viral DNAemia and viral disease was significantly
Figure 1. Cumulative incidence of viral DNAemia until day1100 in pa-
tients with or without lymphocytic engraftment at 2 months post-HSCT.
Lymphocyte engraftment is defined as achievement of absolute lympho-
cyte counts above the second standard deviation of age-dependent
reference values (0-2 years,.2500/mL; 2-5 years,.1500/mL;.5 years,
.1000/mL).
Table 2. Risk Factors for CMV-/EBV-DNAemia
Risk Factor Patients CMV-DNAemia
Rate of
CMV-DNAemia P
Type of disease .014
Nonmalignant 10 6 60%
Malignant 30 5 17%
Recipient serostatus .006
CMV-R+ 18 9 50%
CMV-R- 22 2 9%
EBV-DNAemia
Rate of
EBV-DNAemia
Type of disease .571
Nonmalignant 10 5 50%
Malignant 30 14 47%
Recipient serostatus .592
EBV-R+ 32 15 47%
EBV-R- 8 4 50%
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus.
Table 3. Univariate Analysis of Risk Factors for Viral
DNAemia
Risk Factor (Competing Events) P OR 95% CI
Stem cell source (PBSC vs BM) 0.03 0.38 0.16-0.90
Disease (malignant vs nonmalignant) 0.13 0.53 0.23-1.22
Unrelated donor (related vs unrelated donor) 0.32 0.66 0.30-1.49
Donor CMV seropositivity (CMV-D-/CMV-D+) 0.38 1.43 0.65-3.15
Recipient CMV seropositivity
(CMV-R-/CMV-R+)
0.06 0.47 0.21-1.04
HLA mismatch ($9/10 vs <9/10) 0.02 0.32 0.12-0.86
HLA mismatch (10/10 vs <10/10) 0.12 0.51 0.22-1.19
HLA mismatch (6/6 vs <6/6) 0.99 0.98 0.13-7.30
HLA C mismatch (no vs yes) 0.35 0.65 0.27-1.61
In vivo T cell depletion (no ATG vs ATG) 0.03 0.37 0.15-0.90
Only CsA for GVHD prophylaxis (no vs yes) 0.22 1.85 0.69-4.95
aGVHD (0-2 vs 3-4) 0.25 2.33 0.55-9.94
Lymphocytic engraftment (no vs yes) 0.30 2.48 0.45-13.57
At 2 months (no vs yes) 0.15 2.08 0.78-5.57
At 3 months (no vs yes) 0.51 1.31 0.58-2.95
At 6 months (no vs yes) 0.38 0.64 0.24-1.74
At 9 months (no vs yes) 0.97 1.02 0.37-2.82
At 12 months (no vs yes) 0.67 1.25 0.45-3.45
PBSC indicates peripheral blood stem cell; BM, bone marrow, CMV,
cytomegalovirus; CsA, cyclosporine; GVHD, graft-versus-host disease;
aGVHD, acute graft-versus-host disease.
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NMD, 6/10 patients [60%] vs MD, 7/30 patients
[23%], P 5 .028; viral disease: NMD, 6/10 patients
[60%] vsMD, 3/30 patients [10%], P5 .003). Overall,
viral loads of all patients suffering from viral disease
exceeded the defined viral thresholds and in half of
the patients (5/10 patients [50%]), an increase of viral
load by at least 1 logarithmic degree was detected
before development of viral disease.
This is particularly true for CMV. Five of 11
patients (45%)withCMV-DNAemia developed readily
treatable CMV disease, 3 developed pneumonia, and 2
developed hepatitis. CMV occurred in 4 of 10 patients
in the NMD group (40%), compared with 1 of 30 pa-
tients in theMDgroup (3%;P5 .01).Overall, recipient
CMV seropositivity independent of donor CMV status
was significantly associated with CMV-DNAemia
(P 5 .006) (Table 2). Recurrent CMV DNAemia was
detected in only 2/11 patients (18%) for a total of three
times. CMV-DNAemia was not statistically significant
influenced by in vivo T cell depletion with ATG, which
was administered in 24 patients (CMV1/ATG1,
7/24 patients [29%] vs CMV1/ATG-, 4/16 [25%];
P 5 .533). Nevertheless, CMV load was limited in
patients who did not receive ATG, whereas it
exceeded 4  103 K/mg DNA in ATG-treated patients
(Figure 2). Interestingly, 7/11 patients with CMV-
DNAemia tested positive for at least one other virus,
predominantly EBV (6/11 patients [55%]).
Recipient EBV seropositivity was seen in 15 of the
19 children with EBV-DNAemia (Table 2). In con-
trast to CMV, recurrent viral DNAemia was more
frequent and occurred a total of 11 times in 8 of the
19 patients who were positive for EBV-DNA (42%).
Two EBV pneumonias, 1 EBV hepatitis, and 1 EBVgastritis, were observed, but PTLD was not seen.
Three of these 4 patients with EBV disease (75%)
received in vivo T cell depletion with ATG. In addi-
tion, EBV-DNAemia was clearly associated with the
use of ATG (EBV1/ATG1, 15/24 patients [63%];
EBV1/ATG-, 4/16 [25%]; P 5 .027). As in CMV,
the observed EBV loads were remarkably higher in
the patients receiving ATG (Figure 2). Of note, EBV
loads in the 4 patients with non-PTLD EBV disease
did not exceed 104 copies/mg DNA.
Only 2 of 40 patients (5%) fulfilled our predefined
HHV6 criterion of.500 mg/DNA triggering preemp-
tive GCV therapy. One of these patients had mild
HHV6 pneumonia. Low levels of HHV6 were seen
more frequently, with 110 single and 26 double
HHV6 detections up to 102 copies/mg DNA, which
Figure 2. Viral loads of CMV-, EBV-, and HHV6-DNAemia depending on ATG administration. The bars represent the percentages of patients tested
positive for CMV, EBV, and HHV6 in the depicted ranges of increasing viral loads (1-500, 501-4000, and.4000 K/mg DNA). Distributions are shown for
the respective patient groups receiving conditioning with ATG (ATG1) or without ATG (ATG-).
1432 Biol Blood Marrow Transplant 16:1428-1435, 2010S. Scho¨nberger et al.disappeared without any clinical symptoms or treat-
ment. There was only 1 case each of ADV and BKV
viremia (2.5%), both in the same patient, who also
had EBV disease earlier.
In our entire cohort, severe aGVHDwas rare, with
only 5 of 40 patients (12.5%) suffering from grade III
aGVHD and no patient developing grade IV aGVHD
or dying because of GVHD. Accordingly, there was no
association between severe GVHD and viral DNAemia
(Table 3). The overall low rate of GVHD might result
from the efficacy of ATG in unrelatedHSCT, as well as
from the high degree of HLA matching. Indeed, viral
DNAemia up to day 1100 occurred more frequently
in the ATG-treated patients (Figure 3A) and in those
undergoing\9/10 HLA-matched HSCT (Figure 3B).
Multivariate analysis identified anti–T cell pro-
phylaxis with ATG, HLA mismatch, recipient CMV
seropositivity, and stem cell source as independent
risk factors for viral DNAemia (Table 4).
In our heterogeneous risk group of patients with
malignant and nonmalignant diseases, 6 of 40 patients
(15%) died of transplantation-related complications.
No deathswere attributed to viralDNAemia or disease.DISCUSSION
This is the first report of a prospective and compre-
hensive PCR-guided viral monitoring program for
children with both malignant and nonmalignant dis-
eases undergoing unmanipulated allogeneic HSCT.
Because the use of ATG critically influences T cell
effector function even in T cell–replete HSCTs fromunrelated donors, an analysis of the potential benefits
of stringent viral monitoring in such a pediatric cohort
is clearly warranted.
Of note, 63% of our patients tested positive for
viral DNA at least once. Yet preemptive GCV therapy
limited the extent of viral DNAemia and the manifes-
tation of viral disease such that no death from viral
DNAemia or disease occurred in our cohort. We
opted for a combination of prophylactic acyclovir
administration and preemptive GCV therapy to avoid
potential negative side effects of GCV prophylaxis in
the early posttransplantation period, such as pro-
nounced hematologic toxicity and slower immune
reconstitution after HSCT [8]. Furthermore, prophy-
lactic GCV has been associated with a higher rate of
bacterial infection and secondary neutropenia, but no
improvement in rates of viral detection and disease
[9]. Restricting GCV treatment only to those patients
in our cohort with relevant viral DNAemia, limits the
duration of GCV treatment with the potential to
interfere with the graft.
Generally, the occurrence of viral DNAemia is
determined by the capacity of the immune system to
control viral replication. Consistently, the majority
of cases of viral DNAemia were detected within the
first 100 days posttransplantation. With a cumulative
incidence of 71%, patients without lymphocytic
engraftment at 2 months posttransplantation were at
considerably greater risk for developing viral DNAe-
mia compared with patients with prompt lymphocyte
reconstitution (Figure 1). The impaired immune
system in nonmalignant diseases such as SCID, and
the comparatively low number of transplanted T cells
Figure 3. Cumulative incidence of viral DNAemia up to day1100 de-
pending on ATG as part of the conditioning regimen (A) or the degree of
HLA-matched HSCT (B).
Biol Blood Marrow Transplant 16:1428-1435, 2010 1433Viral Monitoring in Children Undergoing Allogeneic HSCTin BM grafts, might be reasons why BM as a stem cell
source was identified as a statistically significant risk
factor for viral DNAemia (Tables 3 and 4).
In addition to immune deficiency posttransplanta-
tion, several other factors might modulate the antiviral
immune response. Viral replication is thought to act as
a trigger for GVHD and has been associated with
GVHD in several reports [10-15]. In contrast, in our
analysis, viral DNAemia or disease was not
correlated with GVHD. However, ATG-mediatedTable 4. Independent Risk Factors for Viral DNAemia by
Multivariate Analysis
Risk Factor (Competing Events) P OR 95% CI
Stem cell source (PBSC vs BM) .001 0.134 0.042-0.431
HLA mismatch ($9/10 vs <9/10) .036 0.301 0.098-0.923
Recipient CMV seropositivity
(CMV-R-/CMV-R+)
.015 0.335 0.139-0.807
In vivo T cell depletion (no ATG vs ATG) .041 0.331 0.115-0.956
PBSC indicates peripheral blood stem cell; BM, bone marrow; CMV,
cytomegalovirus; ATG, antithymocyte globulin.immune suppression resulted in a higher rate of viral
DNAemia (Figures 2 and 3A; Tables 3 and 4),
underscoring the need for a comprehensive viral
monitoring program in the setting of in vivo T cell
depletion to facilitate prompt initiation of
preemptive GCV therapy when indicated.
Another possible reason for the low incidence of
viral disease in our cohort compared with previous
reports might be that we ensured a good HLA match
between recipients and donors. As our analysis
showed (Figure 3B; Tables 3 and 4), a mismatch in
high-resolution HLA typing, especially in more than
one antigen, promoted viral DNAemia. This finding
is in agreement with other reports demonstrating
a greater risk for viral DNAemia and disease in
HLA-mismatched HSCT using high-resolution HLA
typing [16-18].
Besides the risk factors known to affect the number
and/or function of T cells post-HSCT, such as HLA
match, anti–T cell prophylaxis with ATG, and BM as
the stem cell source, our multivariate analysis identified
recipientCMVseropositivity as an independent risk fac-
tor for viralDNAemia.The28%rateofCMVdetection
in our cohort is comparable to the 24% reported in
a previous pediatric study of 125 recipients of fully
HLA-matched or haploidentical HSCT after ex vivo
and/or in vivo T cell depletion [19]. In another exclu-
sively ex vivo T cell–depleted cohort, the rate of CMV
detection was considerably higher, with 17 of 41
(41.5%) children positive for pp65 antigenemia [20].
Besides recipient CMV seropositivity, our univariate
analysis identified nonmalignant disease as significantly
associatedwith the development ofCMV-DNAemia, in
agreement with several previous studies [12,19-23].We
excluded ATG as a risk factor for CMV by detecting
a nearly equal rate ofCMV-DNAemia between patients
receiving ATG and those not receiving ATG. CMV
viral loads were higher in the ATG group, however
(Figure 2).
We found similar results for EBV, with 25% of
ATG-treated patients exhibiting viral loads above the
previously published critical thresholds of .4  103
or 104 copies/mg DNA, putting HSCT recipients at
particular risk for the development of EBV disease
[24,25]. With prompt initiation of GCV (which is
known to inhibit viral replication) in our cohort, viral
loads ranging between 103 and 104 copies/mg DNA
dropped by 1 log below these critical values within 3
weeks after initial viral detection. Low EBV-
DNAemia might even resolve without any specific
treatment, as demonstrated in our pediatric cohort, in
concordance with a previous large retrospective analy-
sis in adults [26].
None of our patients progressed to PTLD, as was
expected for a well–HLA-matched cohort receiving
unmanipulated stem cells [27]. In contrast, in mixed ex
vivo and in vivo T cell–depleted cohorts, ATG has
1434 Biol Blood Marrow Transplant 16:1428-1435, 2010S. Scho¨nberger et al.been identified as a risk factor for PTLD [24,28-32].
Because rituximab and/or T cell therapy for treatment
and prevention of PTLD are available, the use of
antiviral pharmaceuticals for preemptive therapy
warrants a risk-adapted differential treatment approach
[33]. Recently published guidelines provide several
suggestions for standardizing EBV therapy, focusing
on patients after ex vivo T cell–depleted HSCT
[27,34,35]. In an optimally HLA-matched cohort, pre-
emptive intervention with GCV might be sufficient to
keep viral replication at lower, noncritical levels, avoid-
ing unnecessary rituximab treatment [25,36], which is
associated with profound immune suppression and
possiblywithother critical infectious complications [37].
Data on clinically relevant levels of viral HHV6
loads in pediatric HSCT are sparse. Studies using
low HHV6 copy number limits in children and adults
have reported a high incidence of HHV6-DNAemia,
ranging from 50% to 80% [2,14,17,38,39]. In our
cohort, low-level HHV6-DNAemias, up to 102 cop-
ies/mg DNA, also were detected frequently, but with
no clinical symptoms and with spontaneous resolution
of HHV6 positivity. Even with the use of a higher
HHV6 threshold for initiation of preemptive GCV
therapy, the risk of HHV6-associated morbidity
remains low.
The incidence of ADV and BKV was remarkably
low in our cohort of patients undergoing optimally
HLA-matchedT cell–repleteHSCT. In contrast, other
studies of pediatric and adult cohorts who received
either ex vivo or in vivo T cell–depleted grafts have
reported an ADV incidence of 21%-27% and a BKV
incidence of 10%-33% [40-43], underscoring the
significant risk of ADV and BKV disease in T cell–
depleted HSCT [44,45]. Despite the low incidence in
patients undergoing T cell–replete HSCT, BKV-
DNAemia is strongly associated with the development
of renal impairment and other morbidities after
HSCT [46]; thus, BKV monitoring is essential to
determine critical BKV loads in peripheral blood.
In conclusion, even in T cell–replete HSCT, com-
prehensive PCR-guided viral monitoring is critically
important to identify patients at risk, especially for re-
current or simultaneous viral DNAemia and disease.
We have demonstrated that prophylactic acyclovir
and timely preemptive therapy with GCV is adequate
to prevent viral diseases in pediatric HSCT, especially
those resulting from CMV or EBV, with nearly equal
overall survival rates of patients with and without viral
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